In comparison to p16-negative HNSCC patients, significantly superior 5-year OS, 5-year DFS, and 5-year LRFS outcomes were seen in p16-positive patients (5-year OS 63% vs 40%, p=0.032, 5-year DFS 61% vs 36%, p=0.033, and 5-year LRFS 93% vs 68%, p=0.018, Figure 3A-C). This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.